MESO · Mesoblast Limited
AI read · Good for MESO
The AI's read
Mesoblast finished patient dosing in its Phase 3 rexlemestrocel-L trial, targeting chronic low back pain and a market the company cites above $10 billion. Expanded enrollment to 350 and RMAT status strengthen the headline. The market reacted fast, pushing MESO roughly +10% intraday, so some optimism is already priced. RSI sits mid-range at 46.67, not an overbought blowoff. We lean bullish because the catalyst is company-specific and meaningful, but final judgment waits for mid-2027 top-line data. Expect a binary outcome and elevated volatility until then.